SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Clinical safety rating: safe
No significant drug interactions May cause hypersensitivity reactions including anaphylaxis.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
| Metabolism | Sitagliptin is metabolized primarily via CYP3A4 and to a lesser extent CYP2C8. Metformin is excreted unchanged in the urine; no hepatic metabolism. |
| Excretion | Metformin: 90% renal unchanged (active tubular secretion), 10% fecal. Sitagliptin: 87% renal (active tubular secretion), 13% fecal (biliary excretion minimal for sitagliptin, but fecal includes unabsorbed drug). |
| Half-life | Metformin: Terminal half-life ~6.2 hours (plasma), but prolonged to ~17.6 hours in renal impairment; clinical context: dosing interval adjusted for CrCl. Sitagliptin: Terminal half-life ~12.4 hours, allows once-daily dosing. |
| Protein binding | Metformin: Negligible (<5%), not bound to plasma proteins. Sitagliptin: 38% bound, primarily to albumin. |
| Volume of Distribution | Metformin: 3.11 L/kg (large, due to extensive tissue distribution; clinical meaning: accumulates in erythrocytes, kidney, liver). Sitagliptin: 198 L (oral), approximately 2.8 L/kg; clinical meaning: extensive distribution into tissues. |
| Bioavailability | Metformin: 50-60% (oral, immediate-release), 30-40% (extended-release); food decreases absorption. Sitagliptin: 87% (oral); food does not affect. |
| Onset of Action | Metformin: Onset of glucose-lowering effect 1-3 days, full effect 1-2 weeks (oral). Sitagliptin: Onset of DPP-4 inhibition within 1 hour, clinical glucose lowering seen within 1-2 weeks (oral). |
| Duration of Action | Metformin: Duration of glucose-lowering effect 24 hours (extended-release) or 8-12 hours (immediate-release); clinical note: administered once or twice daily. Sitagliptin: DPP-4 inhibition sustained for 24 hours, supporting once-daily dosing; clinical effect persists with continued use. |
Oral, initial dose based on prior therapy and glycemic control: 50 mg sitagliptin / 500 mg metformin twice daily or 50 mg sitagliptin / 1000 mg metformin twice daily. Max sitagliptin 100 mg/day, metformin 2000 mg/day.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥45 mL/min/1.73 m²: no adjustment. eGFR 30-44: do not initiate; if currently on therapy, reduce dose to 50 mg sitagliptin / 500 mg metformin once daily. eGFR <30: contraindicated. Metformin contraindicated in acute renal impairment. |
| Liver impairment | Contraindicated in Child-Pugh class B and C due to metformin: risk of lactic acidosis. No specific guidelines for Child-Pugh A; use cautiously. |
| Pediatric use | Not approved for patients <18 years of age. Efficacy and safety not established. |
| Geriatric use | Start at lowest dose (50 mg sitagliptin / 500 mg metformin once daily) due to age-related renal decline. Monitor renal function regularly. Avoid if eGFR <45. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions May cause hypersensitivity reactions including anaphylaxis.
| FDA category | Animal |
| Breastfeeding | Sitagliptin: Unknown if excreted in human milk; animal studies show milk excretion. Metformin: Excreted in human milk in low amounts; M/P ratio 0.3–0.6; relative infant dose <1% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding; monitor infant for hypoglycemia or gastrointestinal effects. |
| Teratogenic Risk |
■ FDA Black Box Warning
Lactic acidosis associated with metformin accumulation; rare but serious, occurs primarily in patients with significant renal impairment.
| Common Effects | Nasopharyngitis |
| Serious Effects |
["Severe renal impairment (eGFR <30 mL/min/1.73m2)","Acute or chronic metabolic acidosis (including diabetic ketoacidosis)","Hypersensitivity to sitagliptin or metformin"]
| Precautions | ["Lactic acidosis (discontinue if suspected; avoid in renal impairment, hepatic disease, acute heart failure, dehydration, or alcohol abuse)","Pancreatitis (discontinue if suspected)","Severe and disabling arthralgia","Bullous pemphigoid","Hypoglycemia (when used with insulin or sulfonylureas)","Renal impairment (monitor renal function; contraindicated if eGFR <30 mL/min/1.73m2)","Vitamin B12 deficiency (long-term metformin use)"] |
Loading safety data…
| Sitagliptin: No adequate human data; animal studies suggest low risk. Metformin: Limited human data; not associated with major malformations in first trimester; may reduce risk of early pregnancy loss in PCOS. Second/third trimester: Metformin may be used for GDM; no evidence of fetal harm. Overall: FDA Pregnancy Category B for metformin; sitagliptin not categorized. Caution advised. |
| Fetal Monitoring | Maternal: Blood glucose, HbA1c, renal function (serum creatinine, eGFR), hepatic function (LFTs), lactic acidosis symptoms (for metformin). Fetal: Ultrasound for growth, anatomy, and amniotic fluid volume; consider fetal echocardiogram if sitagliptin used in first trimester. Neonatal: Monitor for hypoglycemia after delivery if metformin continued. |
| Fertility Effects | Metformin may improve ovulation and pregnancy rates in women with PCOS by reducing hyperinsulinemia and androgen levels. Sitagliptin effects on fertility not established; animal studies showed no impairment at clinically relevant doses. In males, no significant effects reported. |